CLAIMS

1. A crystalline form of the bis-HCl salt of a compound represented by Structural Formula 1:

(1)



wherein the crystalline form is Form I and is characterized by at least three x-ray powder diffraction peaks at 2θ angles selected from 7.22°, 7.80°, 10.41°, and 11.11°, wherein the crystalline form is a dihydrate and hemi-ethanolate co-solvate.

2. The crystalline form of claim 1, wherein the crystalline form is characterized by at least four x-ray powder diffraction peaks at 2θ angles selected from 7.22°, 7.80°, 8.19°, 10.41°, and 11.11°.

3. The crystalline form of claim 1, wherein the crystalline form is characterized by at least five x-ray powder diffraction peaks at 2θ angles selected from 7.22°, 7.80°, 8.19°, 10.41°, 11.11°, 15.00°, 16.47°and 20.44°.

4. The crystalline form of claim 1, wherein the crystalline form is characterized by x-ray powder diffraction peaks at 2θ angles of 7.22°, 7.80°, 8.19°, 10.41°, and 11.11°.

5. The crystalline form of claim 1, wherein the crystalline form is characterized by x-ray powder diffraction peaks at 2θ angles selected from 7.22°, 7.80°, 8.19°, 10.41°, 11.11°, 15.00°, 16.47°and 20.44°.

6. The crystalline form of claim 1, wherein the crystalline form is characterized by x-ray powder diffraction peaks at 2θ0 angles of 7.22°, 7.80°, 8.19°, 10.41°, 11.11°, 12.17°, 13.52°, 15.00°, 15.70°, 16.47°, 19.96°, and 20.44°.

7. The crystalline form of claim 1, wherein the crystalline form is characterized by an x-ray powder diffraction pattern in accordance with that depicted in FIG. 5.

8. A composition, comprising particles of one or mom a crystalline form of a compound represented by the bis HCl salt of Structural Formula 1:

(1)



wherein the crystalline form is

Form I characterized by at least three x-ray powder diffraction peaks at 2θ angles selected from 7.22°, 7.80°, 10.41°, and 11.11°;

and wherein the crystalline form is a dihydrate and hemi-ethanolate co-solvate.

9. A pharmaceutical composition, comprising the composition of claim 8 and a pharmaceutically acceptable carrier.

10. Use of a composition of claim 8 in the manufacture of a medicament for treating or preventing an infection caused by bacteria.

11. The use of claim 10, wherein the infection is caused by a Gram-positive bacterium.

12. The use of claim 10, wherein the infection is caused by a Gram-negative bacterium.

13. A composition of claim 8 for use in therapy.